Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Glioblastoma × cediranib × Clear all

Phase

Phase 2 3 Phase 1 3 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 3 Fallopian Tube Neoplasms 2 Neoplasms 1 Glioblastoma 1 Colorectal Neoplasms 1

Interventions

Temozolomide 35 Radiotherapy 16 Lomustine 10 Bevacizumab 10 Carmustine 7 Radiation 6 Procarbazine 4 Surgical Procedures, Operative 3 Magnetic Resonance Spectroscopy 3 pembrolizumab 2 Tf-CRM107 2 Radiotherapy, Intensity-Modulated 2 Drug Therapy 2 Dihematoporphyrin Ether 2 DNA Methylation 2 Carboplatin 2 trans-sodium crocetinate 1 tofacitinib 1 sargramostim 1 rindopepimut 1 niraparib 1 marizomib 1 edotecarin 1 depatuxizumab mafodotin 1 contrast agent BR1 1 cediranib 1 carmustine, poliferprosan 20 drug combination 1 Vincristine 1 Valproic Acid 1 TVB-2640 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00777153 2016-12-28

REGAL

AstraZeneca

Phase 3 Completed

423 enrolled 13 charts

Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡